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1. Abstract 
Objective: Pyrrole-imidazole (PI) polyamide is a class of compounds consisting of 
N-methylpyrrole (Py) and N-methylimidazole (Im), which is able to bind to the minor 
groove of double-stranded DNA in a sequence-specific manner. PI polyamide is 
considered to be an attractive compound for anti-tumor drug development because of 
its tumor-targeting property; however, its molecular mechanism(s) remains largely 
elusive. The primary structure of PI polyamide might affect its physicochemical 
property and thereby influencing its biodistribution. In the present study, we examined 
the effects of chemical composition of PI polyamide on its tumor accumulation in vivo.  
Methods: PI polyamide-fluorescein conjugates with the distinct number of Im units 
were synthesized by a solid-phase peptide synthesis. The degree of hydrophobicity was 
determined by the retention time of high performance liquid chromatography. The 
biodistribution of these compounds in xenograft tumor-bearing mice was analyzed by 
an in vivo fluorescence imaging system. 
Results: There existed an inverse relationship between the number of Im rings of the 
compounds and the degree of hydrophobicity. All compounds accumulated rapidly 
within xenograft tumors regardless of their primary structures. Highly hydrophobic 
compounds showed long-term retention in tumor tissues compared to less hydrophobic 
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compounds. Additionally, hydrophobic compounds accumulated mainly in livers, 
while less hydrophobic compounds detected predominantly in kidneys. 
Conclusion: The present results suggest that the composition of PI polyamide, which 
contributes to its hydrophobic property, has an implication for its accumulation and 
retention in tumor tissues in vivo. 
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2. Introduction 
Pyrrole-imidazole (PI) polyamide is a class of compounds consisting of 
N-methylpyrrole (Py) and N-methylimidazole (Im) aromatic amides originally derived 
from natural oligopeptide antibiotics, such as distamycin A. While distamycin A 
non-covalently binds to the minor groove of adenine (A) and/or thymine (T) -rich DNA 
sites,
1
 PI polyamides possess a similar specificity for nucleotide binding and improved 
base recognition, where Im recognizes guanine (G) and Py binds to A, T, and cytosine 
(C).
2-4
 PI polyamide physically associates with the minor groove of double-stranded 
DNA without distorting the helical structure, especially in a -aminobutyric acid-linked 
hairpin configuration.
5
 This class of molecules affords binding affinities comparable to 
certain transcription factors.
6
 As such, well-designed PI polyamides targeting to 
promoter and enhancer elements of the genes of interested could interrupt the assembly 
of transcription factors, such as TFIIIA,
7
 AP-1,
8, 9
 and HIF-1,
10
 and thereby repressing 
its gene expression. 
As aberrant gene expressions as a result of genetic and epigenetic abnormalities have 
been well implicated in various diseases, the use of PI polyamides presents an attractive 
option for the development of novel drugs against those diseases. Recently, a PI 
polyamide targeting to the promoter of TGFB1 successfully ameliorated progressive 
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renal diseases
9
 and hypertrophic scars.
11
 Another PI polyamide against an androgen 
receptor responsible element (ARE) was able to repress the ARE-regulated gene 
transcriptions, e.g. VEGF and TMPRSS2-ERG, a unique prostate cancer-related 
oncogenic fusion gene, and thereby suppressing the xenograft tumor growth of human 
prostate cancer cells.
12, 13
 Our recent study of a PI polyamide against oncogenic driver 
mutant genes KRAS
G12D/V
 demonstrated differential cytotoxicity in vitro and repressed 
tumor growth in mouse xenograft models in vivo without severe adverse effects such as 
body weight loss,
14
 highlighting the promising aspect of PI polyamides in drug 
development. 
While the ability for PI polyamides to accumulate in certain tissues has been revealed 
in several studies, the underlying physiochemical principles remain unclear. Recent 
studies showed PI polyamides to accumulate into skin xenograft tumors
15, 16
 and vital 
organs such as liver, kidney, and lung,
17
 but so far there are few explanations for such a 
phenomenon. Previously, Fukasawa et al. proposed that the plasma level of 
intravenously administrated PI polyamide increased positively as their molecular 
weight,
18
 and Kamei et al. hypothesized a potential connection between the Py/Im ratio 
of a polyamide and its plasma level in vivo.
19
 As results from Best et al. echoed similar 
sentiments to the hypothesis that the primary structure of a PI polyamide affected a 
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molecule’s distribution in vivo, we sought to characterize the potential connection here, 
as few studies have systematically examined the biodistribution of PI polyamides in 
vivo
20
 and no general design roles on how to utilize the pharmacokinetic profiles of PI 
polyamides to improve its accumulation/retention, biological elimination and 
organ/tissue distribution for therapeutic puroposes. 
In the present study, we have designed a series of hairpin ten-ring PI polyamides with 
distinct ratios of Py and Im units to infer the possible effect of hydrophobicity, as 
governed by the number of Im units, on the molecular machinery of their internalization 
into tumor tissues in vivo. While all PI polyamides rapidly accumulated into tumor 
tissues, PI polyamides with higher Im unit numbers displayed longer retention times in 
tumor tissues compared to their counterparts with lower Im unit numbers, suggesting 
that the primary structure of PI polyamide did in fact affect its tissue distribution in 
vivo. Thus, the hydrophobic property of PI polyamide or other properties resulting from 
its chemical compositions might be implicated in its pharmacodynamic properties. 
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3. Materials and Methods 
3.1 General materials 
Human colon cancer-derived cell lines LS180 and SW480 were obtained from 
American Tissue Culture Collection (Manassas, VA, USA). PyBOP and NovaPEG 
Wang resin were acquired from Novabiochem (Gibbstown, NJ, USA); unless otherwise 
specified, chemicals were obtained from Sigma-Aldrich (St. Louis, MO, USA). 
 
3.2 Chemical synthesis of pyrrole-imidazole (PI) polyamide-fluorescein conjugates 
Compounds 1-5 were piecewise synthesized by first generating the polyamide 
backbone chains (1, -PyIm--PyPyPy--PyPyPy--PyPy; 2, 
-ImIm--PyPyPy--PyPyPy--PyPy; 3, -ImIm--ImPyPy--PyPyPy--PyPy; 4, 
-ImIm--ImImPy--PyPyPy--PyPy; 5, -ImIm--ImImIm--PyPyPy--PyPy) by 
stepwise Fmoc solid-phase reaction using a PSSM-8 solid-phase peptide synthesizer 
(Shimadzu Industry, Kyoto, Japan) at 10 μmol scales of Fmoc--alanine NovaPEG 
Wang resin as previously described.
39
 After the synthesis, N, N-Dimethyl-1, 
3-propanediamine (Wako, Tokyo, Japan) was mixed with the resin at 65 ºC for 2 hours 
for compound cleavage. PI polyamides having the carboxyl-terminal amine was purified 
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by a Prominence high-performance liquid chromatography (HPLC) (Shimadzu Industry, 
Kyoto, Japan) using a 10 mm×150 mm Gemini-NX3u 5-ODS-H reverse-phase column 
(Phenomenex, Torrance, CA, USA) in 0.1% acetic acid in water with acetonitrile as 
eluent, at a flow rate of 10 mL/minute, and a linear gradient from 0% to 66.7% 
acetonitrile over 20 minutes, with ultraviolet detection at 310 nm. Collected polyamide 
backbones were conjugated with fluorescein as previously described.
20
 In brief, the 
polyamides were dissolved in N-methylpyrrolidone with fluorescein-4-Isothiocyanate 
(FITC; 5 equivalents, Dojindo, Kumamoto, Japan) and N, N-Diisopropylethylamine (10 
equivalents, Wako, Tokyo, Japan). After reaction at room temperature for 2 hours, the 
resulting polyamide-fluorescein conjugates were purified by HPLC as described 
conditions and analyzed by an LCMS-2020 liquid chromatograph mass spectrometer 
(LC MS) system (Shimadzu Industry, Kyoto, Japan) using a 150 x 4.6 mm Gemini-NX 
3u 11A reverse-phase column (Phenomenex, Torrance, CA, USA). 1: LC-MS m/z 
calculated for C101H111N29O20S, [M+2H]
2+
 1041.92; found 1042.25, [M+3H]
3+
 694.94; 
found 695.15. 2: LC-MS m/z calculated for C100H110N30O20S, [M+2H]
2+
 1042.41; found 
1042.90, [M+3H]
3+
 695.27; found 695.55. 3: LC-MS m/z calculated for C99H109N31O20S, 
[M+2H]
2+
 1042.91; found 1043.40, [M+3H]
3+
 695.61; found 695.95. 4: LC-MS m/z 
calculated for C98H108N32O20S, [M+2H]
2+
 1043.41; found 1043.85, [M+3H]
3+
 695.94; 
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found 696.25. 5: LC-MS m/z calculated for C97H107N33O20S, [M+2H]
2+
 1043.91; found 
1044.30, [M+3H]
3+
 696.27; found 696.55.  
 
3.3 Estimation of logPOW value 
The logPOW values were estimated by using reverse-phase HPLC as previously 
described
40
. In brief, retention times of compounds were measured by using a 
Prominence HPLC system (Shimadzu Industry, Kyoto, Japan) using a 150 x 4.6 mm 
Gemini-NX 3u 11A reverse-phase column (Phenomenex, Torrance, CA, USA) with 
performed in an isocratic condition (0.1% acetic acid : acetonitrile = 4 : 1) at a flow rate 
of 1 mL/minute. A standard curve was constructed by plots of the logPOW values versus 
retention times of reference substrates, such as ethyl acetate,
41
 benzonitrile,
41
 
acetophenone
41
 and indole
42
, and then logPOW values of PI polyamides were estimated 
by their retention times. 
 
3.4 Fluorescence quantum yield 
Fluorescence spectra were measured by an FP-8600 spectrometer (JASCO, Tokyo, 
Japan) and corrected with correlation functions for excitation and mission optics 
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obtained by use of an SID-844 calibration detector (JASCO, Tokyo, Japan). Absorption 
spectra were recorded by a UV-2400PC spectrometer (Shimadzu Industry, Kyoto, 
Japan). 
Fluorescence quantum yield (∅f) was estimated by the relative method using a 
formula, 
 
 
in which, ∅, F, A, and n are the quantum yield, the integrated fluorescence intensity, the 
absorbance at excitation wavelength, and the refractive index of solvent used, 
respectively, and subscript x and s stand for sample of interest and standard sample, 
respectively. Fluorescein in 1 mM NaOH/EtOH was used as standard sample (∅f = 
0.92).
43
 
 
3.5 In vitro experiments 
Human colon cancer-derived LS180 and SW480 cells were maintained with 
minimum essential medium (MEM, Gibco Life technology, Carlsbad, CA, USA) and 
Dulbecco’s modified eagle medium (DMEM, Wako, Osaka, Japan) supplemented with 
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10 % heat-inactivated fetal bovine serum (FBS; Invitrogen, Carlsbad, CA, USA) and 50 
g/ml penicillin/streptomycin (Sigma-Aldrich, St. Louis, MO, USA) in a humidified 
atmosphere with 5 % CO2 at 37 °C.  
For in vitro PI polyamide incorporation analysis, human colon cancer cells (1 x 10
5
 
cells) were grown on glass coverslips and treated with 1 M of each compound for 2 
hours. Cells were then washed twice with ice-cold PBS and fixed with 100% methanol 
for 20 minutes at -20 °C. Coverslips were mounted with VECTACHIELD Mounting 
Hard Set Medium with DAPI (Invtitrogen, Carlsbad, CA, USA). Fluorescence images 
were observed under a DMI 4000B confocal laser microscope (Leica Microsystems, 
Wetzlar, Germany).  
For in vitro fluorospectrometric analysis, human colon cancer cells (1 x 10
4
 cells) 
were treated with compounds 1, 3, and 5 at the indicated doses for 24 hours. Cells were 
washed twice in PBS. Fluorescence intensity was determined by an ARVO X-3 
fluorescence spectrometer (Perkin Elmer, Franklin Lakes, NJ, USA). 
 
3.6 Animal experiments 
3.6.1 Ethics statement 
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Procedures involving animals outlined in the following section satisfied guidelines 
described in the Proper Conduct of Animal Experiments as defined by the Science 
Council of Japan. Approval from the Animal Care and Use Committee on the Ethics of 
the Chiba Cancer Center Institute was obtained prior to experimentation. All 
experimental steps were carefully performed to ensure the subjects endured minimal 
suffering.  
3.6.2 Xenograft tumor model 
Human colon cancer-derived LS180 (3 x 10
6
 cells/mouse) were maintained as 
described above and subcutaneously inoculated into left flanks of 5- to 8-weeks female 
BALB/c nude mice (Oriental Yeast, Tokyo, Japan). Compounds 1, 3, 5, or FITC (1 
mg/kg), or DMSO/PBS (1.25%, v/v) was intravenously administrated into the 
tumor-bearing mice when the long diameter of xenograft tumors reached about 1 cm. 
Fluorescence images of the whole mice were captured at the indicated time points 
post-administration and the fluorescence intensity of tumor and non-tumor areas were 
analyzed on a Lumazone imaging system (Roper Bioscience, Tucson, AZ, USA).  
For detection of compounds 1, 3, and 5 in tissues, the mice were sacrificed at 3 days 
or 9 days after administration for resection of the following tissues: tumor, liver, kidney, 
heart, lung, spleen, and brain were resected. Frozen sections were prepared and 
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observed under a DMI 4000B confocal laser microscope (Leica Microsystems, Wetzlar, 
Germany). Mean fluorescence intensity of tissue sections obtained from the PI 
polyamide-treated mice (n = 3) was determined by using a WinROOF version 7.0 
software (Mitani Corporation, Tokyo, Japan).  
 
3.7 Statistical analysis 
Results were presented as mean ± SD of three independent experiments. Data were 
compared using the unpaired t-test, one-way ANOVA, and repeated-measure two-way 
ANOVA by Ekuseru-Tokei 2010 software (Social Survey Research Information Co., 
Ltd., Tokyo, Japan) and p-value < 0.05 was considered to be significant. 
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4. Results 
4.1 Molecular design and synthesis of PI polyamide-fluorescein conjugates 
To examine whether the compositional variation of PI polyamides could affect its 
hydrophobicity, we designed five PI polyamide-fluorescein conjugates with different 
compositions of Im units: 1-5 (Figure 1). Im units were located at positions 1 through 7 
in hairpin configurations to avoid Im/Im pairings as previous studies suggested that 
such pairing had no preferential affinity for G-C or A-T pairs.
3
 According to the 
previous studies, -alanine () and -aminobutyric acid () residues were incorporated 
in order to allow the polyamides to be flexible and the hairpin-like structure, 
respectively.
5, 21, 22
 The designed PI polyamide–fluorescein conjugates 1–5 were 
synthesized via the Fmoc solid-state peptide synthesis procedure followed by a 
conjugation of fluorescein with PI polyamides at their N-termini as described in 
Materials and Methods. Purities (> 96%) of the resulting PI polyamide–fluorescein 
conjugates were confirmed by a high performance liquid chromatography (HPLC), and 
these compounds were used for following experiments (Figure 2).  
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4.2 The number of imidazole units of PI polyamide reflects its hydrophobicity  
A molecule’s equilibrium partitioning in a biphasic water and n-octanol system, as 
determined by its logPOW, is a common indicator for the hydrophobicity, measureable 
from their HPLC corresponding retention times.
23
 We thereby measured the retention 
times of compounds 1-5 and reference compounds, such as ethyl acetate, benzonitrile, 
acetophenone, and indole (Figure 3), and likewise deduced the logPOW values of 1-5 
from their recorded retention times (Table 1). Compound 1 with only one Im unit 
exhibited the highest logPOW value, while 5 with five Im units showed the lowest the 
logPOW value among these compounds. In addition, the logPOW values of 2-4 were 
gradually reduced along with the increase in the number of Im units. These results 
suggested a clear inverse correlation between logPOW values of compounds 1-5 and 
their respective number of Im units.  
In the meantime, we analyzed the fluorescence of each polyamide as a precaution to 
confirm that fluorescence of fluorescein moiety did not vary resulting from a function of 
the chemical structure of the PI polyamide adduct. We saw an increase in the level of 
fluorescence quantum yield of compounds 1-3 with their Im unit numbers; however, it 
was decreased in compounds 4 and 5 (Table 1). Consistently, compounds 1, 2 and 5 
displayed similar fluorescence, while 3 and 4 had the highest and the lowest 
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fluorescence intensity, respectively (Figure 4). Because 4 showed the lowest 
fluorescence intensity and hydrophobicity of 2 was similar to 1, we employed three 
compounds for further experiments: 1 as a highly hydrophobic compound, 3 as a 
moderately hydrophobic compound, and 5 as a relatively hydrophilic compound.  
 
4.3 A mode of internalization of PI polyamide-fluorescein conjugates into 
tumor-derived cells 
We next examined the incorporation of PI polyamide-fluorescein conjugates by 
tumor-derived cells in vitro by fluorescent microscopy. Human colon cancer LS180 and 
SW480 cells were treated with 1, 3, and 5 followed by 4′, 6-diamidino-2-phenylindole 
(DAPI) staining. Consistent with previous studies,
8, 20, 24
 1, 3, and 5 strongly 
co-localized with DAPI, indicating that these compounds highly accumulated in cell 
nuclei regardless of the distinct hydrophobicity (Figure 5a and 5b). Fluorescein was 
undetectable in the cells (Figure 5a and 5b). 
We further investigated how PI polyamide-fluorescein conjugates is incorporated by 
cells. LS180 and SW480 cells were treated with various concentrations of compounds 
and measured fluorescence intensity by a fluorescence spectrometer. As seen in Figure 
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5c and 5d, 1 was internalized into LS180 and SW480 cells in a dose-dependent manner, 
whereas the dose dependency was not seen in 3 or 5. These data suggested that 
hydrophobic PI polyamides were likely incorporated by tumor-derived cells through 
passive diffusion instead of other possible transport mechanisms.  
 
4.4 Accumulation of hydrophobic PI polyamides into tumor in vivo 
To test whether the hydrophobicity of compounds 1, 3, and 5 could affect its 
tumor-oriented distribution in vivo, we intravenously injected 1, 3, 5, alongside 
unconjugated fluorescein or dimethyl sulfoxide (DMSO) as controls, into nude mice 
bearing LS180-derived tumors. The superficial fluorescence of these mice was 
monitored for 72 hours post-administration by quantitative in vivo imaging; the mean 
fluorescence intensity (MFI) in tumor and in non-tumor area was summarized in Figure 
6. In the tumor area, 1 showed an increase in the level of MFI with a peak at 3 hours 
post-administration that sustained over 72 hours (Figure 6a and 6f). Compound 3 also 
had an elevated MFI in tumors with a peak at 6 hours post-administration, and nearly 
half of its maximum level was still detectable at 72 hours post-administration (Figure 6b 
and 6g); the MFI of 5 in the tumors reached its maximal level at 3 hours 
post-administration and it became undetectable at 48 hours post-administration (Figure 
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6c and 6h). In contrast, we could not detect fluorescence in the tumor tissues of subjects 
injected with unconjugated fluorescein, despite that it did appear to distribute in the 
entire body with similar kinetics to that of 3 (Figure 6d and 6i). This observation 
affirmed that the fluorescence observed in the tumor tissues of polyamide-injected mice 
was in fact due to the conjugated fluorescein moiety on the polyamides. Beyond the 
graft regions, 1 rapidly distributed in the body cavity within 1 hour, and its level sharply 
decreased at 24 hours post-administration (Figure 6a and 6f), whereas 3 experienced a 
spike in MFI in non-tumor areas within 5 minutes but disappeared at 24 hours 
post-administration (Figure 6b and 6g). The level of 5 was almost undetectable in the 
entire body during the experiment (Figure 6c and 6h). Similar proportion of distribution 
of PI polyamide-fluorescein conjugates was seen in another human colon cancer 
SW480-derived tumor bearing mice (Figure 7), collectively suggesting that 
hydrophobicity of PI polyamide influences tumor-oriented distribution. 
 
4.5 Long retention of hydrophobic PI polyamides within tumor in vivo 
Since the half level of 1 and 3 in the tumor seemingly extended beyond 3 days after 
their initial injections, we further investigated long-term retention of PI 
polyamide-fluorescein conjugates in tumor-bearing mice. To this end, we treated the 
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LS180-bearing nude mice with compounds 1, 3, and 5 and monitored the resultant 
fluorescent decay by quantitative in vivo imaging until their fluorescein signal was 
disappeared (Figure 8). The fluorescence of compounds 1, 3, and 5 reached their 
maximal levels around 2 hours post-administration and decreased by half around 48 
hours post-administration. Surprisingly, 1 was still detectable in tumors over 9 days 
post-administration, while 3 did not; additionally, we found the fluorescence of 5 to 
extinguish in a time frame as short as 4 days. Notably, 1 was detectable within 
SW480-derived tumors in vivo for up to 22 days (Figure 9), indicating that increasing 
the hydrophobicity or other properties of the PIP likely contributed to a longer tumor 
retention time in vivo. 
 
4.6 Tissue distribution of hydrophobic PI polyamides 
The results so-far prompt us to analyze further the distribution of PI 
polyamide-fluorescein conjugates in tissue sections. PI polyamide-fluorescein 
conjugates-inoculated animals were resected at 3 days and 9 days post-administration, 
and the tissue fluorescence distribution was assessed by confocal microscopy. 
Compounds 1, 3, and 5 were mainly detectable in tumors, livers and kidneys at 3 days 
post-administration, and appeared to co-localize with DAPI, implying that PI 
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polyamide-fluorescein conjugates accumulated in the nucleus in vivo (Figures 10-12). 
There was no fluorescence in any of the regions tested in DMSO-treated mice (Figure 
13). We further measured the MFIs in these tissue sections. As shown in Figure 14a, 1 
accumulated preferentially in tumors, and the liver to a smaller extent, and poorly 
presented in the kidney and spleen on 3 days post-administration. At the same time, 3 
was detected in tumors as well as kidneys, but accumulation in the liver was relatively 
low (Figure 14b). Compound 5 was largely detected in kidneys compared to tumors and 
livers (Figure 14c). Compound 1 remained notably detectable in tumor at 9 days 
post-administration (Figure 14a). In contrast, levels of 3 and 5 in tumor tissues largely 
decreased at 9 days post-administration (Figures 14b and 14c), suggesting that the 
hydrophobic property influences the biodistribution of PI polyamides in vivo. 
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5. Discussion 
5.1 Effect of chemical structure of PI polyamide on its hydrophobicity 
We herein have synthesized a series of PI polyamides 1-5 with different number of 
Im units to confer the distinct hydrophobicity. Given that the presence of an additional 
nitrogen atom of Im affected its propensity for hydrogen bonding, the degree of 
hydrophilicity of Im (logPOW = -0.06) is larger than that of Py (logPOW = 1.21)
25, 26
. In 
comparison with their logPOW values, the hydrophobicity of 1 was approximately twice 
higher than that of 5. Thus, the hydrophilic level of PI polyamide might be correlated 
with the number of Im units. In this study, all of Im units were located at the positions 
before the  unit of compounds 1-5 to simplify their chemical structure. According to 
the extensive studies as reviewed,
27
 the position of Im unit served a critical role in the 
specificity of PI polyamide for the recognition of DNA; thereby, their positions would 
be scattered throughout the molecule in a nucleotide-sequence dependent manner. It was 
possible that the different composition of Im units could influence the hydrophobicity of 
PI polyamide despite the same numbers of Im units; therefore, the measurement of 
logPOW by using HPLC should be required for the development of PI polyamide-based 
medicine.  
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5.2 Effects of hydrophobic structures of PI polyamides on tumor-oriented 
accumulation and retention 
In the present study, we demonstrated for the first time that the retention time of PI 
polyamide in tumor tissue was inversely correlated with its Im unit numbers: compound 
1 with only one Im unit was detectable within tumor tissues longer than 3 with three Im 
units, whereas 5 with five Im units could no longer be found after 3 days. Additionally, 
1 retained in tumors over 22 days, a longer retention time compared to previous 
studies.
15
 Similarly, the most hydrophobic 1 was delivered into tumor tissues much 
higher than compounds 3 and 5. Because the fluorescence intensities of compounds 1, 3, 
and 5 were nearly equal, we speculated that the hydrophobic level of PI polyamides is 
involved in its tumor-oriented delivery.  
Tumor cells activated tumor-associated angiogenesis upon the deprivation of oxygen 
and nutrients accompanying the tumor growth, and thereby accelerating growth of 
tumor tissues.
28
 Raskatov et al. demonstrated an increased accumulation of PI 
polyamides in tumors in vivo as a function of relationship between xenograft host and 
tumor tissue, such as tumor vascularization.
29
 It has been considered that tumor vascular 
system is different from blood vessels in normal organs, such as defective vascular 
architecture and deficiency of lymphatic drainage from tumor tissue.
30
 Additionally, 
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many kinds of macromolecules like plasma proteins as well as lipids predominantly 
accumulated and retained in tumor tissues, so-called the enhanced vascular permeability 
and retention (EPR) effect.
31, 32
 As Chenoweth et al. demonstrated that certain PI 
polyamides strongly bind to plasma proteins,
33
 we hypothesized that the Im unit 
numbers of PI polyamide, which partly contributes to the degree of hydrophobicity, 
would have an impact on its association with plasma proteins or lipids, resulting in its 
accumulation into tumor tissue, at least in part mediated by the EPR effect. Our 
histological examination supported a similar notion that the hydrophobic PI polyamide 
1 in tumor tissue was distributed by the surrounding blood vessels (Figure 15); however, 
more detail analysis of the binding affinities of PI polyamides to plasma proteins and 
the relationship between hydrophobicity of PI polyamides and histological distribution 
in tumor tissues would need to be clarified. 
We also have demonstrated for the first time that the mode of internalization of PI 
polyamide into tumor-derived cells is associated with the Im unit numbers. Because of a 
dose dependent internalization of 1, hydrophobic PI polyamide might penetrate into 
cells within tumor tissues through the passive diffusion. In contrast, certain transport 
systems could be involved in the incorporation of relatively hydrophilic 3 and 5. Since 
certain mechanisms to uptake extracellular substrates were activated in tumor cells via 
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oncogenic signaling pathway,
34
 it could be possible that higher activation of endocytosis 
in tumor cells is responsible for the higher uptake of PI polyamides compared to normal 
organs. However, further examination to uncover how the tumor cells incorporate PI 
polyamides remains to be elucidated.  
 
5.3 A hydrophilicity-mediated distribution and excretion of PI polyamide 
Another important finding of the present study was the effect of the hydrophobicity of 
a PI polyamide’s biodistribution in vivo. Consistent with previous studies,15, 29, 35 the 
hydrophobic 1 was preferentially delivered into livers as well as tumors; however, the 
hydrophilic 5 was predominantly accumulated in kidneys. Our in vivo imaging analysis 
also demonstrated that hydrophilic 5 was rapidly cleared from the body relative to the 
hydrophobic 1 and 3, suggesting that the serum/tissue half-life of PI polyamides in vivo 
is associated with its hydrophilicity. 
Various drugs are eliminated from the body by renal and/or bile excretion. Harki et al. 
described that a hairpin-formed PI polyamide would firstly be transported in the liver 
and then delivered into bladder rather than gallbladder, implying a possible mode of 
renal excretion.
35
 We saw a rapid decrease in the circulation level of 5 at an earlier time 
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point than that of 1 and 3. As the fluorescence intensity of 1, 3, and 5 was nearly equal, 
the likely explanation was that an increase in the hydrophilic level of PI polyamide 
elevates the rate of its renal excretion as a result of “kidney-homing”. Intriguingly, the 
moderately hydrophobic 3 was observed in both tumors and kidneys, and remained in 
tumors longer than 5, suggesting that the hydrophilicity of a PI polyamide contributed 
to its tumor-homing but not liver-homing property in vivo. In support of our hypothesis, 
Synold et al. also demonstrated that acetylating PI polyamide could potentially increase 
its hydrophobicity to the extent of altering localization in tissues such as livers, kidneys 
and lungs and rapidly reducing its plasma concentration.
36
 Additionally, several 
chemical modifications at -turn37 and PEGylation at the carboxyl terminus38 affected 
the hydrophobicity of PI polyamide. Thus, an increase in the hydrophilic level of PI 
polyamide might reduce adverse effect of PI polyamide-based medicine resulting from 
the modulation of biodisribution in vivo, especially the reduction of “liver-homing” 
property. 
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6. Conclusion 
PI polyamides with different Im unit numbers were synthesized and examined for their 
differences in tissue distribution within tumor bearing mice. The Im unit numbers of PI 
polyamides were contributed to a polyamide’s hydrophobicity in a manner that affected 
its accumulation and retention in tumor tissues as well as its internalization into 
tumor-derived cells in vitro. Intriguingly, we found that moderately hydrophobic PI 
polyamides decline the ability of “liver-homing” compared to highly hydrophobic 
polyamides, suggesting that well-designed PI polyamides potentiate the “tumor-homing” 
ability and can be utilized as a novel drug delivery system to reduce adverse effects to 
unintended regions of the body. 
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9. Appendices 
Table 1. Partition coefficients (logPOW) and fluorescence quantum yield (f
a
) of 
compounds 1-5. 
 
Compound retention time (min) logPOW f
a
 
1 11.73 1.50 0.022 
2 11.40 1.46 0.026 
3 10.97 1.42 0.027 
4 10.48 1.36 0.010 
5 8.86 1.19 0.014 
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Figure 1. Chemical structures and graphical schemas 
of the pyrrole-imidazole polyamide-fluorescein 
conjugates 1-5 employed in this study 
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Figure 2. LC MS analysis of compuonds 1-5  
MS spectra of compounds 1 (a), 2 (b), 3 (c), 4 (d), and 5 (e). 
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Figure 3. Chromatograms of compounds 1-5 and reference compounds 
Chromatograms of indicated compounds were obtained by high pressure liquid 
chromatography and their retention times were shown: compounds 1 (a), 2 (b), 3 (c), 4 (d), 
5 (e), ethyl acetate (f), benzonitrile (g), acetophenone (h), and indole (i). Phenacetin is 
used as an internal standard for compounds 1-5. A standard curve was plotted for the 
retention times and the logPOW values (j).  
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Figure 4. Fluorescence of compounds 1-5 
10 M of compounds 1-5 were incubated with the 100 µL of 
DMSO/PBS solution (1% v/v) at 37 °C. Sixty minutes after 
the incubation, their fluorescence intensities were measured 
by an ARVO X3 fluorescence spectrometer (PerkinElmer, 
MA, USA). Data shows mean ± SD of independent three 
experiments.  
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Figure 5. Nuclear uptake and fluorescence intensity of compounds 1, 3, and 5  
in colon cancer cells 
(a and b) Human colon cancer LS180 (a) and SW480 (b) cells were treated with 
PI polyamide-fluorescein conjugates 1, 3, 5, FITC, or DMSO. Cells were stained 
with DAPI and images shown are captured under confocal laser microscopy 
(magnitude: x 630), with scale bars indicating 20 m. (c and d) LS180 (c) and 
SW480 (d) cells were treated with compound 1, 3, or 5 at the indicated doses or 
left untreated for 24 hours at 37 °C. The fluorescence of these cells was 
determined by fluorospectrometer. Data show mean ± SD of triplicate samples. 
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Figure 6. Representative images of 1, 3, and 5-treated mice and their mean 
fluorescein intensities of tumor and non-tumor areas 
Human colon cancer LS180 cells were subcutaneously inoculated into flanks of 
nude mice. Compounds 1 (a), 3 (b), 5 (c), FITC (d), or 1.25% DMSO/PBS (e) was 
intravenously administrated into the tumor-bearing mice (1 mg/kg) upon 
approximately 1 cm of growth for in vivo fluorescent imaging. The fluorescence 
images of whole bodies of the treated mice were then taken by an in vivo imaging 
system at the indicated time points post-administration. Circles mark the tumor and 
the non-tumor areas for measuring fluorescein intensity. The mean fluorescent 
intensities at the tumor (closed circles) and at the non-tumor area (open circles) of 
tumor-bearing mice inoculated with compounds 1 (f), 3 (g), 5 (h), FITC (i), and 
DMSO (j) are shown; error bars indicate SD (n = 3, *p < 0.05, **p < 0.01). 
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Figure 7. The biodistribution of PI polyamides in tissue sections prepared from 
PI polyamide-treated mice 
Human colon cancer SW480 (5 x 10
6
 cells/mouse, a-j) or LS180 (3 x 10
6
 
cells/mouse, k-t) cells were subcutaneously inoculated into flanks of nude mice. 
Either compound 1 (a, k), 3 (b, l), 5 (c, m), FITC (d, n), or 1.25% DMSO/PBS (e, o) 
was intravenously administrated into the tumor-bearing mice (n = 3) when the long 
diameter of xenograft tumors reaches approximate 1 cm. The fluorescence images of 
their entire bodies were then taken by an in vivo imaging system at the indicated 
time points post-administration. Representative images are shown and circles in the 
images are indicated as tumor and non-tumor areas for measurement of fluorescein 
intensity. The mean fluorescent intensities at tumor (closed circles) and at non-tumor 
skin area (open circles) of tumor-bearing mice inoculated with compounds 1 (f, p), 2 
(g, q), 3 (h, r), FITC (I, s), and DMSO (j, t) are shown; error bars indicate SD (n = 3, 
*p < 0.05, **p < 0.01). 
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Figure 8. Percent of mean fluorescence intensities at tumor 
areas was measured for 9 days after administration 
Human colon cancer LS180 cells were subcutaneously inoculated 
into flanks of nude mice. All injections were performed 
intravenously (1 mg/kg) upon approximately 1 cm of growth. 
Mice with the PI polyamide-fluorescein conjugate 1 (closed 
squares), 3 (closed triangles) and 5 (closed circles) were 
monitored at the indicated time points post-administration. The 
fluorescence intensity at 0 hours (before administration) and 2 
hours was taken for 0% and 100%, respectively. Results show 
mean ± SD (n = 3 mice per group, **p < 0.01). 
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Figure 9. The bio-distribution of PI polyamides in tissue sections prepared from 
PI polyamide-treated mice 
(a) Human colon cancer-derived SW480 cells (5 x 10
6
 cells per mouse) were 
subcutaneously inoculated into left flanks of 5- to 8-weeks female BALB/c nude 
mice (Oriental Yeast, Tokyo, Japan). Compound 1 (1 mg/kg) or 1.25% DMSO/PBS 
was intravenously administrated into the tumor-bearing mice when the long 
diameter of xenograft tumors reaches about 1 cm, and these mice were monitored at 
the indicated time points post-administration. Circles mark the tumor and the 
non-tumor areas for measuring fluorescein intensity. (b and c) The mean fluorescent 
intensities at the tumor (closed circles) and at the non-tumor area (open circles) of 
mice with compounds 1 (b) or 1.25% DMSO/PBS (c) are shown. Results show 
mean ± SD (n = 3 mice per group, **p < 0.01). 
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Figure 10. The fluorescent image of tissue sections prepared from compound 
1-treated mice 
Human colon cancer-derived LS180 cells (3 x 10
6
 cells per mouse) were 
subcutaneously inoculated into left flanks of 5- to 8-weeks female BALB/c nude 
mice (Oriental Yeast, Tokyo, Japan). Compound 1 (1 mg/kg) was intravenously 
administrated into the tumor-bearing mice when the long diameter of xenograft 
tumors reaches about 1 cm. The mice were sacrificed at 3 days or 9 days after 
administration and then tumor, liver, kidney, heat, lung, spleen, and brain were 
resected. Frozen sections were prepared and observed under a DMI 4000B confocal 
laser microscope (Leica Microsystems, Wetzlar, Germany). Bars indicate 50 m. 
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Figure 11. The fluorescent image of tissue sections prepared from compound 
3-treated mice 
Human colon cancer-derived LS180 cells (3 x 10
6
 cells per mouse) were 
subcutaneously inoculated into left flanks of 5- to 8-weeks female BALB/c nude 
mice (Oriental Yeast, Tokyo, Japan). Compound 2 (1 mg/kg) was intravenously 
administrated into the tumor-bearing mice when the long diameter of xenograft 
tumors reaches about 1 cm. The mice were sacrificed at 3 days or 9 days after 
administration and then tumor, liver, kidney, heat, lung, spleen, and brain were 
resected. Frozen sections were prepared and observed under a DMI 4000B confocal 
laser microscope (Leica Microsystems, Wetzlar, Germany). Bars indicate 50 m. 
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Figure 12. The fluorescent image of tissue sections prepared from compound 
5-treated mice 
Human colon cancer-derived LS180 cells (3 x 10
6
 cells per mouse) were 
subcutaneously inoculated into left flanks of 5- to 8-weeks female BALB/c nude 
mice (Oriental Yeast, Tokyo, Japan). Compound 3 (1 mg/kg) was intravenously 
administrated into the tumor-bearing mice when the long diameter of xenograft 
tumors reaches about 1 cm. The mice were sacrificed at 3 days or 9 days after 
administration and then tumor, liver, kidney, heat, lung, spleen, and brain were 
resected. Frozen sections were prepared and observed under a DMI 4000B confocal 
laser microscope (Leica Microsystems, Wetzlar, Germany). Bars indicate 50 m. 
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Figure 13. The fluorescent image of tissue sections prepared from 
DMSO-treated mice 
Human colon cancer-derived LS180 cells (3 x 10
6
 cells per mouse) were 
subcutaneously inoculated into left flanks of 5- to 8-weeks female BALB/c nude 
mice (Oriental Yeast, Tokyo, Japan). DMSO/PBS (1.25%, v/v) was intravenously 
administrated into the tumor-bearing mice when the long diameter of xenograft 
tumors reaches about 1 cm. The mice were sacrificed at 3 days or 9 days after 
administration and then tumor, liver, kidney, heat, lung, spleen, and brain were 
resected. Frozen sections were prepared and observed under a DMI 4000B confocal 
laser microscope (Leica Microsystems, Wetzlar, Germany). Bars indicate 50 m. 
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Figure 14. Fluorescein intensities of tumors and indicated organs from 1, 3, or 
5-treated mice (3 and 9 days) 
Tissue sections of tumors and various organs were prepared from LS180-derived 
tumor-bearing mice with the PI polyamide-fluorescein conjugates 1 (a), 3 (b), 5 (c), 
or DMSO (d) as a vehicle control at 3 days and 9 days post administration. Their 
fluorescence was captured under a confocal laser microscope and quantitated their 
fluorescence intensity. Data shows mean ± SD, n = 3 mice per group, **p < 0.01. 
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Figure 15. Distribution of compound 1 along with tumor blood vessels 
Human colon cancer-derived LS180 cells (3 x 10
6
 cells per mouse) were subcutaneously 
inoculated into left flanks of 5- to 8-weeks female BALB/c nude mice (Oriental Yeast, Tokyo, 
Japan). Compound 1 (1 mg/kg) was intravenously administrated into the tumor-bearing mice 
when the long diameter of xenograft tumors reaches about 1 cm. Mice were sacrificed at 3 
days after administration. Tumor tissues were fixed in 4% paraformaldehyde (Nacalai tesque, 
Kyoto, Japan) for 16 hours at 4 °C and embedded in paraffin (Leica biosystems, Eisfeld, 
Germany). The paraffin-embedded sections were deparaffinized in 10 mM citrate buffer (pH 
6.0) for 10 min at 90 °C. After blocking of nonspecific reactivity with blocking buffer (Protein 
Block Serum-Free; DAKO, Tokyo, Japan), tissue sections were incubated with primary 
antibodies against fluorescein (x 100, Abcam, Cambridge, UK), murine CD34 (x 250, Novus 
Biologicals, Littleton, CO, USA), or respective control rat or rabbit IgG (Immuno-Biological 
Laboratories Co, Ltd.), ) for 16 hoursat 4 °C, followed by incubation with secondary 
antibodies Alexa488-conjugated anti-rabbit IgG (x 500, Invitrogen, Carlsbad, CA, USA) and 
Alexa546-conjugated anti-rat IgG  (x 500, Invitrogen) for 1 hours at room temperature. 
Sections were mounted with VECTASHIELD Mounting Medium with DAPI (Vector 
Laboratory, Burlingame, CA, USA) and visualized under a DMI6000 CS microscope (Leica 
Microsystems, Wetzlar, Germany). Compound 1 in tumor tissue is preferentially distributed 
along with CD34-positive blood vessels. Arrows indicate fluorescence from residual 
compound 1. Bars indicate 200 µm.  
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